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Introduction: Stem cells have been evaluated as a potential therapeutic approach for several neurological
disorders of the central and peripheral nervous system as well as for traumatic brain and spinal cord injury.
Currently, the lack of a reliable and safe method to accurately and non-invasively locate the site of implantation
and track the migration of stem cells in vivo hampers the development of stem cell therapy and its clinical
application.
In this report, we present data that demonstrate the feasibility of using the human sodium iodide symporter (hNIS)
as a reporter gene for tracking neural stem cells (NSCs) after transplantation in the brain by using single-photon
emission tomography/computed tomography (SPECT/CT) imaging.
Methods: NSCs were isolated from the hippocampus of adult rats (Hipp-NSCs) and transduced with a lentiviral
vector containing the hNIS gene. Hipp-NSCs expressing the hNIS (NIS-Hipp-NSCs) were characterized in vitro and
in vivo after transplantation in the rat brain and imaged by using technetium-99m (99mTc) and a small rodent
SPECT/CT apparatus. Comparisons were made between Hipp-NSCs and NIS-Hipp-NSCs, and statistical analysis was
performed by using two-tailed Student’s t test.
Results: Our results show that the expression of the hNIS allows the repeated visualization of NSCs in vivo in the
brain by using SPECT/CT imaging and does not affect the ability of Hipp-NSCs to generate neuronal and glial cells
in vitro and in vivo.
Conclusions: These data support the use of the hNIS as a reporter gene for non-invasive imaging of NSCs in the
brain. The repeated, non-invasive tracking of implanted cells will accelerate the development of effective stem cell
therapies for traumatic brain injury and other types of central nervous system injury.Introduction
During the past decade, several reports have explored
the therapeutic potential of neural stem cells (NSCs) for
the treatment of neurological disorders of the central
nervous system (CNS) (i.e., macular degeneration,
Parkinson’s disease, Alzheimer’s disease, and multiple
sclerosis) and for traumatic brain and spinal cord injury
[1–8]. However, the successful development of stem cell
therapy and its translation to the clinical setting is cur-
rently hampered by the lack of a reliable and safe
method to accurately monitor the location, migration,
and phenotypical differentiation of transplanted cells. So* Correspondence: mmicci@utmb.edu
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article, unless otherwise stated.far, the majority of preclinical studies on stem cell fate
have relied on ex vivo histological analysis of green fluor-
escent protein (GFP) or β-galactosidase expression in
the grafted cells. These analyses require the euthanasia
of the animals at each time point studied and therefore
are laborious and time-consuming. Recently, the devel-
opment of in vivo non-invasive imaging technologies has
provided the means to monitor the delivery, grafting,
and survival of stem cells. Current imaging modalities to
monitor cells in the brain include magnetic resonance
imaging (MRI), single-photon emission tomography
(SPECT), positron emission tomography (PET), bio-
luminescence, and fluorescence imaging [9].
The use of fluorescence and luciferase for biolumines-
cence imaging is an excellent tool to monitor grafted
cells in small animals but is not translatable to theis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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imaging modalities that are suited for human use. Al-
though MRI has a higher spatial resolution than SPECT/
PET, the sensitivity of detection is higher for SPECT/PET
than MRI (SPECT/PET: 10−10–10−12 M levels of probe;
MRI: 10−3–10−5 M levels of probe). Additionally, PET has
the ability to detect reporter genes [10, 11].
The use of reporter genes to track stem cell fate
in vivo is particularly appealing, as it is the only method
that allows studying stem cell survival (only viable cells
will be able to express the reporter protein), proliferation
(the reporter gene will be passed on to daughter cells,
and the corresponding imaging signals will increase in
intensity), and death (cells that are apoptotic or dead will
not be able to express the reporter protein). Moreover, a
reporter gene can be placed under cell-specific pro-
moters (e.g., neuron-specific or glia-specific), thus allow-
ing monitoring of the fate of the transplanted cells
within the host tissue [12, 13].
When clinicians decide on which reporter gene to use
for imaging stem cells, important factors to be consid-
ered are (1) biological distribution of the gene, (2) avail-
ability of the probes, and (3) effect of the expression of
the reporter gene on the physiology of the cells.
In this respect, the sodium iodide symporter (NIS)
reporter gene represents a good choice for imaging
stem cells in the brain because (1) it is not expressed
in the brain, (2) the radio probes for NIS are readily
available in most nuclear medicine clinics and no
radio synthesis is required, (3) the metabolism and
clearance in the body of both radiodiodide and
technetium-99m (99mTc) are well known, and (4) the
imaging potentials of NIS have been shown in vitro
and in vivo [14, 15].
The use of the NIS to monitor in vivo the delivery,
grafting, and phenotypical differentiation of cells after
transplantation has recently been investigated in particu-
lar in cardiovascular research [16–18]. The NIS has also
been used to monitor trafficking of immune cells in vivo.
Seo et al. reported how transfecting immortalized macro-
phage cell lines with the hNIS allowed monitoring of their
migration toward areas of inflammation in vivo in nude
mice by using PET imaging [19].
Up until now, however, no studies have been reported
on the use of the NIS for imaging NSCs in the brain
in vivo. Here, we report on the development of the use
of the NIS for imaging NSCs in the brain.
Methods
Animals
Male Sprague–Dawley rats (200–350 g) were used in all
of the experiments described. Experimental protocols
were approved by the Institutional Animal Care and Use
Committee at the University of Texas Medical Branch,Galveston, in accordance with the guidelines provided
by the National Institutes of Health.Isolation and in vitro expansion of rat hippocampal neural
stem cells
Cell culture reagents were obtained from Invitrogen
(Carlsbad, CA, USA), except where noted. Adult male
Sprague–Dawley rats (200–250 g) were anesthetized
with isofluorane (4 % by inhalation) and euthanized by
decapitation. The brain was rapidly removed, and the
hippocampi were identified and dissected out. The
hippocampi from three or four rats were collected into a
50-ml Falcon tube containing sterile Dulbecco’s modified
Eagle’s medium/F12 (DMEM/F12) medium with antibi-
otics (penicillin and streptomycin) and kept on ice. The
tissue was minced into small pieces in cold Hanks’ Bal-
anced Salt Solution (HBSS) medium containing 1 mM
EGTA in a sterile Petri dish. The tissue pieces were
transferred into a sterile 50-ml tube containing HBSS
(without Ca2+ and Mg2+) with 0.1 % collagenase/dispase,
0.01 % DNase I; 1 ml for 100 mg of tissue) and incu-
bated for 30 min at 37 °C. The tissue was triturated
every 10 min by using a sterile disposable 5-ml pipette.
At the end of the incubation, the cell suspension was
centrifuged at 200×g for 5 min at room temperature
(RT). The pellet was resuspended in HBSS containing
0.025 % trypsin/ethylenediaminetetraacetic acid and incu-
bated for 10 min at 37 °C. An equal volume of DMEM/F12,
2 mM L-glutamine, 10 % fetal bovine serum (FBS), and
antibiotics was added to stop the digestion and the cell
suspension was centrifuged at 200×g for 5 min. The pellet
was resuspended in sterile DMEM/F12 with L-glutamine,
10 % FBS, and antibiotics; triturated by using a 1-ml tip;
and centrifuged. This step was repeated two to four times
until a single cell suspension was obtained. The cell sus-
pension was filtered through a 70-μm Falcon filter, centri-
fuged at 200×g for 5 min, and resuspended in complete
growth medium: neurobasal A medium containing the
serum-free supplement B27 (without retinoic acid), 2 mM
L-glutamine, 20 ng/ml of epidermal growth factor (EGF),
20 ng/ml of basic fibroblast growth factor-2 (FGF-2), and
penicillin/streptomycin. The cells were plated in an un-
coated T25 flask at approximately 1×106 cells per 10 ml of
complete growth medium. The medium was changed after
24 h and every other day after that.Coating of plates with poly-ornithine and laminin
Stock solutions were prepared as follows: poly-L-ornithine
(Sigma-Aldrich, St. Louis, MO, USA, catalog number
P3655) was reconstituted with sterile distilled water at
a concentration of 10 mg/ml, and aliquots were stored
at −20 °C; laminin (1 mg/ml; Invitrogen) was stored
at −20 °C.
Micci et al. Stem Cell Research & Therapy  (2015) 6:131 Page 3 of 16The poly-L-ornithine stock solution was diluted
1:1000 in sterile distilled water to a final working con-
centration of 10 μg/ml and added to the plates as follow:
1.5 ml/well of six-well plates; 0.2 ml/well of eight-well
chambered slides (Lab-Tek II Chambered Slide System;
Nalgene Nunc International, Naperville, IL, USA). Plates
and slides were incubated overnight at RT and then
washed twice with distilled water, incubated with lam-
inin overnight at RT (10 μg/ml in Dulbecco’s phosphate-
buffered saline (D-PBS) without Ca2+ and Mg2+; 1 ml/
well of six-well plates and 0.2 ml/well of eight-well
chambered slides), and stored at −20 °C until ready to
use. The plates were washed with D-PBS once before
use.
Induction of differentiation
Hipp-NSCs were dissociated into single cells by using
StemPro Accutase (Invitrogen) in accordance with the
instructions of the manufacturer and counted on a
hemocytometer. The cells were plated onto poly-
ornithine/laminin-coated plates as follows: 125,000
cells per well into a six-well plate and 10,000 cells per
well into eight-well chambered slides. To induce differ-
entiation, the cells were cultured for 8–10 days in neu-
robasal A medium containing B27 with retinoic acid,
0.5 mM L-glutamine, 1 % FBS, and penicillin/strepto-
mycin. The medium was changed every other day.
Lentivirus packaging
The full-length human sodium iodide symporter cDNA
(hNIS, a kind gift from Sissy M. Jhiang) was cloned into
the pCDH-CMV-MCS-EF1-copGFP cDNA cloning and
expression lentivector (System Biosciences, Mountain
View, CA, USA). The lentivector product was packaged
into VSV-G pseudotyped viral particles by System Bio-
sciences (titer 3.12×109 infectious units/ml).
Transduction of Hipp-NSCs
Adult rat Hipp-NSCs were dissociated into single cells
by using StemPro Accutase (Invitrogen) in accordance
with the instructions of the manufacturer and counted
on a hemocytometer. The cells were divided into sterile
1.5-ml Eppendorf tubes (100,000 cells per tube in 250 μl
of complete growth medium). Pseudovirus particles
packaged with the lentivector containing the hNIS were
added to each tube at 5, 10, 20, and 40 multiplicity of in-
fection, and the tubes were incubated at 37 °C in a 5 %
CO2 incubator for 30 min. The cells were then trans-
ferred to a 24-well plate (250 μl of cells was added to
750 μl of complete growth medium per well) and placed
in a 5 % CO2 incubator at 37 °C. After 48 h, the cells
were collected into a sterile 15-ml conical tube, centri-
fuged at 200×g for 5 min, resuspended in complete
growth medium, and plated out into a sterile T75 flask.The medium was changed every other day. Expression
of GFP (indicative of transduction efficiency) was moni-
tored by using an inverted fluorescent microscope
equipped with a 488-nm excitation filter (Nikon Eclipse
TS100; Nikon, Tokyo, Japan).
Fluorescence-activated cell sorting
Transduced Hipp-NSCs were dissociated into single
cells by using StemPro Accutase, resuspended in sterile
D-PBS containing 1 % bovine serum albumin at a con-
centration of 10–20×106 cells/ml, and passed through a
70-μm Falcon filter. The cells were kept on ice and
brought to the University of Texas Medical Branch
(UTMB) Flow Cytometry Core Facility, where they were
run through a FACSAria cell sorter (BD Biosciences, San
Jose, CA, USA). The cells were sorted on the basis of
the expression of GFP and collected into a 15-ml tube
containing 1 ml of complete growth medium with 10
mM HEPES. The collected cells were centrifuged and
replated in fresh complete growth medium.
In vitro uptake of technetium-99m
99mTc was obtained from the Department of Nuclear
Medicine at UTMB. Cells (Hipp-NSCs expressing the
hNIS and naïve Hipp-NSCs not transduced) were plated
out into a six-well plate at a density of 500,000 cells/ml
(1.5×106 cells per well) in complete growth medium.
The cells were incubated with 99mTc (3–5 μCi/well) for
30 min at 37 °C in a 5 % CO2 incubator and then
washed with ice-cold PBS two times by collection and
centrifugation at 200×g for 5 min. At the end of the last
centrifugation, the cells were lysed in 500 μl of NaOH
(0.33 M) containing 1 % SDS. Counts per minute
(CPMs) were read on a gamma counter. Baseline read-
ings were obtained from tubes containing NaOH-1 %
SDS and no cells. Data were corrected by subtracting
the baseline reading averaged from three separate mea-
surements from the sample CPMs.
Cell proliferation assay
Cell proliferation was measured by using the CellTiter
96 Aqueous non-radioactive cell proliferation assay
(Promega Corporation, Madison, WI, USA). This assay
is based on the principle that a tetrazolium compound
([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS)) is
converted by viable cells into a soluble formazan product
that can be measured by reading the absorbance at 490 nm.
Briefly, Hipp-NSCs and Hipp-NSCs transduced with the
hNIS were dissociated into single cells by using StemPro
Accutase, plated out into a 96-well plate (10,000 and 20,000
cells per well) in complete growth medium (100 μl/well),
and cultured for 24–48 h. At the desired time point, 20 μl
of MTS/PMS solution (prepared in accordance with the
Table 1 List of antibodies used for the phenotypical
characterization of Hipp-NSCs and hNIS-Hipp-NSCs













Mouse anti-NeuN Mature neurons 1:2000 WB Millipore
1:1000 IF




Oligodendrocytes 1:200,000 IF Millipore
Mouse anti-hNIS Human NIS 1:100 IF Abcam
Hipp-NSC hippocampus-derived neural stem cell, hNIS-Hipp-NSC
hippocampus-derived neural stem cell expressing the human sodium iodide
symporter, WB Western blot, IF immunofluorescence, anti-GFAP anti-glial fibrillary
acidic protein
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and the plate was incubated for 3–4 h at 37 °C in a humidi-
fied incubator, 5 % CO2 atmosphere. The plate was read in
an enzyme-linked immunosorbent assay plate reader (Mo-
lecular Devices, Sunnyvale, CA, USA) at 490 nm. Back-
ground absorbance was measured from wells that were
loaded with complete growth medium only and to which
MTS/PMS was added.
Total protein extraction and Western Blot Analysis
Cells growing as neurospheres in complete growth
medium were collected in a 15-ml conical tube and cen-
trifuged at 200×g for 5 min at RT. The cells were resus-
pended in D-PBS and centrifuged again. RIPA lysis
buffer containing protease inhibitor cocktail, phosphat-
ase inhibitors cocktail, and 100 μM phenylmethylsulfo-
nyl fluoride (PMSF) (all from Sigma-Aldrich) was added
to the cell pellet (150–250 μl of lysis buffer for 2–5×106
cells). The lysed cells were transferred to 1.5-ml Eppen-
dorf tubes, vortexed, and incubated on ice for 5 min and
then quickly frozen in liquid nitrogen and stored at −80 °C.
Cells growing on poly-ornithine/laminin-coated plates
were detached by using StemPro Accutase, collected into
15-ml tubes, and centrifuged at 200×g for 5 min. The
cell pellet was washed in D-PBS and lysed in RIPA lysis
buffer as described above. Total protein content was
measured by using a Pierce BCA protein assay kit
(Thermo Scientific, Rockford, IL, USA).
The protein samples were processed for SDS-
polyacrylamide gel electrophoresis (PAGE) with XCell
SureLock® Mini-Cell (Invitrogen). After electrophoresis,
proteins were transferred to polyvinylidene difluoride
(PVDF) membranes (Bio-Rad Laboratories, Hercules,
CA, USA) overnight at 4 °C. Blots were incubated in
blocking buffer (5 % non-fat dry milk in Tris-buffered
saline containing 0.1 % Tween 20; TBS-T) for 1 h at RT
and probed with primary antibodies diluted in blocking
buffer overnight at 4 °C. After three washes in TBS-T,
the blots were incubated with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Tech-
nology, Inc., Danvers, MA, USA; 1:200 dilution in block-
ing buffer) for 1 h at RT.
Detection was performed using ECL plus kit (Amersham,
GE Healthcare, Little Chalfont, UK) followed by exposure
of x-ray films (Bioexpress, Kaysville, UT, USA) that were
developed with M35A-X-OMAT Processor (Kodak, Roch-
ester, NY, USA). Band intensities were quantified by using
ImageJ software, and data were normalized to the expres-
sion of the housekeeping protein GAPDH (glyceraldehyde
3-phosphate dehydrogenase).
Immunofluorescence analysis
Cells growing on poly-ornithine/laminin-coated cham-
bered slides were washed in PBS (pH 7.4) and fixed in4 % paraformaldehyde (pH 7.4 in PBS) for 15 min at RT.
After two washes in PBS, the cells were blocked and
permeabilized in PBS containing 5 % normal goat serum
and 0.3 % triton X-100 for 30 min at RT. The cells were
incubated with primary antibodies (Table 1) diluted in
1.5 % normal goat serum in PBS overnight at 4 °C in a
humid chamber. After three washes in PBS, the cells
were incubated with secondary antibodies (1:400; Alexa-
conjugated anti-mouse and anti-rabbit; Invitrogen) in
1.5 % normal goat serum in PBS for 1 h at RT in a
humid chamber. The cells were washed two times in
PBS and once in tap water before being coverslipped with
mounting medium containing DAPI (4′,6-diamidino-2-
phenylindole), a fluorescent stain that binds strongly to A-
T-rich regions in DNA and is used to label cell nuclei
(Vector laboratories, Burlingame, CA, USA). The slides
were viewed with an Olympus BX51 fluorescence micro-
scope equipped with a cooled charge-coupled device
camera (Microfire; Optronics, Goleta, CA, USA) and
image acquisition software (PictureFrame; Optronics).
Injection of Hipp-NSCs in the hippocampus
Hipp-NSCs were labeled with the cell tracker CMFDA
(Invitrogen), suspended at a concentration of 50,000
cells/μl in D-PBS, and kept on ice until ready to inject.
Experimental recipient adult male rats were deeply
anesthetized with isoflurane (2–4 %) and intubated with
an endotracheal tube (6.5-French tubing attached to
16-gauge needle adapter) attached to a ventilator (tidal
volume set at 12–15 cc/kg and breath rate set at ap-
proximately 28–30 breaths per minute). The anesthe-
tized rats were placed at the flat-skull position on a
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was performed. The cells were injected by using a 33-
gauge cannulae supported by the outside 26-gauge
guide cannulae connected with a Hamilton syringe. The
cells were injected into the hippocampal CA1—anter-
ior-posterior (AP): −3.6, medial-lateral (ML): +2.0,
dorsal-ventral (DV): −2.6—and CA3 (AP: −3.6, ML: +3.6,
DV: −3.6) regions (1 μl/site at a speed of 0.2 μl/min). The
number of cells injected was chosen on the basis of the
work by Gao et al. [20].Injection of Hipp-NSCs in the lateral ventricles
Hipp-NSCs were suspended in D-PBS at a concentration
of 2×105 cells/μl. Experimental recipient adult male rats
were deeply anesthetized with isoflurane (2–4 %) and
intubated with an endotracheal tube (6.5-French tubing
attached to 16-gauge needle adapter) attached to a venti-
lator (tidal volume set at 12–15 cc/kg and breath rate
set at approximately 28–30 breaths per minute). The
anesthetized rats were placed at the flat-skull position
on a small animal stereotaxic apparatus, and a craniot-
omy was performed. The injection site was drilled by
using a Dremel drill 1.5 mm posterior to bregma and 1.2
mm to lateral right of sagittal suture for ventricular pres-
sure verification, and injection of cells was performed
(5 μl; 0.2 μl/min).SPECT/CT imaging
Imaging was performed by using an Inveon™ PET-
SPECT-CT system (Siemens Medical Solutions, Knox-
ville, TN, USA) equipped with two gamma cameras (for
SPECT modality) and x-ray source and camera for CT
imaging mounted on a rotating stage. The PET detector
is mounted separately and was not used in this study.
This scanner combines PET, SPECT, and CT modalities
in one system under the control of a single workstation
that allows integrated data acquisition and processing.
CT imaging provides mostly anatomical reference infor-
mation (where the gamma signal comes from), and
SPECT provides functional information showing the in-
tensity and the distribution of the isotope in the body.
Injected in the animal, a gamma-emitted isotope serves
as a source of signal, and the signal is detectable by the
SPECT cameras. Since the isotope (in our study, 99mTc)
is specifically attaching to the cells with NIS (naturally,
to the thyroid cells; in our study, to the modified stem
cells) and is not attaching to the other cells, it provides
the imaging contrast between the signal (coming from
the cells of interest) and background. Cameras are ro-
tated around the animal and the signal collected for 3D
reconstruction. In general, we followed the same CT/
SPECT imaging as described by Terrovitis et al. [16].In vivo SPECT imaging
The rats were anesthetized with isofluorane and posi-
tioned on the bed of the SPECT/CT module with their
nose inside a mask connected to the isofluorane dispen-
ser. High-resolution CT scans were performed before
each SPECT session. The 99mTc signal was co-registered
to the CT scan image by using data processing software
Inveon Research Workspace (Siemens Medical Solutions).
CT parameters were 2048×3072 pixels, 70 kV, 500 μA,
and 520 steps, giving a 3D isotropic resolution of approxi-
mately 0.1 mm. SPECT parameters were 40 projections
and 9-degree step, for a total of about 16 min for one
scan.
Intracerebral cannulation for delivery of 99mTc in the
brain
The rats were anesthetized with isoflurane (2–4 %) and
intubated with an endotracheal tube (6.5-French tubing
attached to 16-gauge needle adapter) attached to a ventila-
tor (tidal volume set at 12–15 cc/kg and breath rate set at
approximately 28–30 breaths per minute). The anesthe-
tized rats were placed at the flat-skull position on a small
animal stereotaxic apparatus, and a craniotomy was per-
formed. A microdialysis CMA guide cannula/probe (BASi,
West Lafayette, IN, USA) was inserted into the hippocam-
pus (Bregma: −4.3 mm; ML: −3.5 mm; Dura: −3.2 mm).
Tissue processing and immunofluorescence analysis
At the desired time point after cell transplantation, the
rats were anesthetized with pentobarbital and cardially
perfused with heparinized saline followed by ice-cold
4 % paraformaldehyde (pH 7.4). The brains were re-
moved and embedded in 20 % sucrose in PBS (pH 7.4).
Sections (20 μm) were cut on a cryostat, collected on
glass microscope slides (Superfrost Plus; Thermo Fisher
Scientific Inc., Marietta, OH, USA), and stored at −20 °
C. For immunofluorescence analysis of grafted cells, the
sections were hydrated in PBS and incubated in PBS
containing 10 % normal goat serum and 0.3 % Triton X-
100 for 30 min at RT. The sections were incubated with
primary antibodies diluted in PBS containing 1.5 % nor-
mal goat serum, overnight at 4 °C and with secondary
antibodies (594 Alexa-conjugated, Invitrogen; 1:400 dilu-
tion in PBS with 1.5 % normal goat serum) for 1 h at
RT. After washing in PBS, the sections were rinsed in
tap water and coverslipped with mounting medium with
DAPI (Vector Laboratories).
Statistical analysis
Data were expressed as the mean ± standard error. Stat-
istical analysis between two independent experimental
groups was performed by using two-tailed Student’s t test.
Results were considered significant for P values of less
than 0.05.
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Expansion and characterization of Hipp-NSCs
NSCs were isolated from the hippocampus of adult rats
and maintained in culture in serum-free neurobasal A
medium supplemented with B27 and the growth factors
EGF and FGF-2 (complete growth medium). Under
these conditions, the cells actively proliferate and form a
characteristic spheroid group of cells that express the
NSC marker nestin (Fig. 1a, b). NSCs are defined not
only by their ability to proliferate and generate daughter
cells that are unspecialized and express specific stem cell
markers but also by their ability to generate neurons and
glia. When Hipp-NSCs were plated onto poly-ornithine/
laminin-coated plates in serum-free medium containing
B27, retinoic acid, and no growth factors (EGF and FGF-
2), they attached to the substrate and underwent rapid
morphological changes (Fig. 1c). Immuncytochemical
analysis of cells grown for 8 days under differentiatingA
C
Fig. 1 Hipp-NSCs form neurospheres and generate neurons and glia in vitro.
medium with EGF and FGF-2. b Immunofluorescence analysis of nestin expre
c Phase-contrast photograph of Hipp-NSCs growing on poly-ornithine-coated
analysis of Hipp-NSCs after 8 days of differentiation showing the expression o
(green). Nuclei are stained blue with DAPI. Scale bars = 50 μm. DAPI 4′,6-diam
growth factor-2, GFAP glial fibrillary acidic protein, Hipp-NSC hippocampus-deconditions confirmed that both neurons and glia were
generated from Hipp-NSCs (Fig. 1d).
Generation of Hipp-NSCs expressing the hNIS
Hipp-NSCs were transduced by using pseudoviral parti-
cles packaged with a lentivector containing the hNIS and
the reporter gene GFP (Fig. 2a, b). The expression of GFP
and fluorescence-activated cell sorting was used to select
out Hipp-NSCs expressing the hNIS (Fig. 2c, d). The ex-
pression of the hNIS in the sorted cells was confirmed by
immunocytochemical analysis (Fig. 2e). We also deter-
mined whether the expression of the hNIS would be
retained after differentiation. Hipp-NSCs transduced with
the hNIS were cultured onto poly-ornithine/laminin-coated
plates in differentiation medium for 7 days. The hNIS was
maintained in the differentiated cells as shown by the ex-
pression of GFP and by immunofluorescence analysis by
using a specific antibody against hNIS (Fig. 2f, g).B
D
a A typical neurosphere formed by Hipp-NSCs growing in serum-free
ssion (red) in Hipp-NSC neurospheres. Nuclei are stained blue with DAPI.
plates in differentiation medium for 8 days. d Immunofluorescence
f the neuronal marker βIII-tubulin (red) and of the glial marker GFAP
idino-2-phenylindole, EGF epidermal growth factor, FGF-2 fibroblast





Fig. 2 (See legend on next page.)
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Fig. 2 Generation of Hipp-NSCs expressing the hNIS. a Map of the HIV-based lentivector CD11B-1 (System Biosciences). The hNIS cDNA was
cloned in the multiple cloning site (MSC) located downstream of the CMV promoter. Downstream of the expression cassette for the hNIS, an EF1
promoter drives the expression of GFP. b Expression of GFP in Hipp-NSCs transduced with pseudoviral particles for 48 h. The fluorescent image is
superimposed on the phase-contrast image. c Flow cytometric analysis of Hipp-NSCs transduced with the hNIS showing the expression of GFP
(indicative of the expression of hNIS) in 62 % of the cells before sorting and in 96 % of the cells after sorting (d). e Immunofluorescence analysis
of the expression of the hNIS (in red) in Hipp-NSCs transduced with the lentivector and selected by sorting for GFP. Nuclei are stained blue with
DAPI. f Expression of GFP in differentiated Hipp-NSCs transduced with the hNIS. g Immunoreactivity for the hNIS in differentiated NIS-Hipp-NSCs.
Nuclei are counterstained blue with DAPI. h Uptake of 99mTc in NIS-Hipp-NSCs was measured as counts per minute (CPM) in a gamma counter and
corrected by subtracting background CPM. N = 3; *P < 0.01 by Student’s t test. Scale bars = 100 μm. CMV cytomegalovirus, DAPI 4′,6-diamidino-
2-phenylindole, GFP green fluorescent protein, Hipp-NSC hippocampus-derived neural stem cell, hNIS human sodium iodide symporter,
NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the human sodium iodide symporter, 99mTc technetium-99m
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NSCs is functional, we tested the ability of the trans-
duced cells to transport 99mTc, a gamma-emitting radio-
isotope that is used by the NIS instead of endogenous
iodide. A significant increase in CPM was measured in
Hipp-NSCs expressing the hNIS as compared with con-
trol Hipp-NSCs not expressing the hNIS and exposed to
99mTc (Fig. 2h).Characterization of Hipp-NSCs expressing the hNIS
in vitro
To assess the effect of the hNIS on cell viability, Hipp-
NSCs were plated in a 96-well plate in neurobasal A
medium containing EGF and FGF (complete growth
medium) at two different densities (10,000 and 20,000
cells per well) and cultured for 24 h. To measure prolif-
eration, the cells were plated out at a density of 10,000
cells per well and cultured for 24 and 48 h. Cell viability
was assessed by using the MTS assay (CellTiter 96
Aqueous non-radioactive cell proliferation assay; Promega
Corporation). No significant differences were detected be-
tween Hipp-NSCs expressing the hNIS (NIS-Hipp-NSCs)
and Hipp-NSCs in their naïve form (not expressing the
hNIS) (Fig. 3a, b). To test the effect of 99mTc incorporation
on cell viability, Hipp-NSCs and NIS-Hipp-NSCs were
exposed to 99mTc (100 μCi added to the cell culture
medium) for 30 min. The cells were washed, resus-
pended in proliferation medium, plated out in a 96-well
plate (10,000 cells per well), and cultured for 48 h. Cell
viability was assessed 48 h later by using the MTS assay
(CellTiter 96 Aqueous non-radioactive cell proliferation
assay). No significant differences were detected between
Hipp-NSCs and NIS-Hipp-NSCs, indicating that the in-
corporation of 99mTc in NIS-Hipp-NSCs does not re-
duce cell viability. In addition to studying the effect of
the hNIS on Hipp-NSC viability and proliferation, we
studied whether NIS-Hipp-NSCs retain their character-
istic stem cell signature. This was done by analyzing the
expression of NSC markers by Western blot analysis.
There was no difference in the expression of nestin andSOX2 between Hipp-NSCs transduced with the hNIS
(NIS-Hipp-NSCs) and naïve Hipp-NSCs (Fig. 3c, d).
Differentiation potential of Hipp-NSCs expressing the
hNIS
To test the effect of hNIS on the ability of Hipp-NSCs
to generate neurons and glia, the cells were plated out
onto poly-ornithine/laminin-coated plates and cultured
for 8 days in neurobasal medium containing B27 with
retinoic acid and 1 % FBS (differentiation medium).
Neuronal and glial differentiation was assessed by im-
munofluorescence and Western blot analysis. The re-
sults show that the expression of hNIS does not affect
the ability of Hipp-NSCs to generate neurons and glia
in vitro (Fig. 4).
SPECT/CT imaging of Hipp-NSCs expressing the hNIS
In vitro imaging
Hippocampus-derived NSCs can be visualized by using
SPECT imaging by providing 99mTc to the cells and
measuring the gamma-ray emission from the cells that
have taken up the 99mTc via the NIS. Hipp-NSCs stably
expressing the NIS were incubated in vitro with 99mTc
and imaged by placing the cells in an Eppendorf tube in-
side the SPECT/CT imaging module. Control cells
(Hipp-NSCs not expressing the NIS) were also incubated
with 99mTc and imaged (Fig. 5a).
In vivo imaging
To assess whether grafted cells can be visualized by
using SPECT/CT imaging in the live animal, in a first
set of experiments we incubated NIS-Hipp-NSCs
in vitro with 99mTc before transplantation in the rat
brain. The cells were injected in the left lateral ventricle
(1×106 cells) (Fig. 5b) or in the hippocampus (two injec-
tion sites per hippocampus; amount of cells per site ran-
ging from 440,000 to 55,000 cells) (Fig. 6a), and the rats
were subjected to SPECT imaging. The SPECT signal
was superimposed to the CT scan to localize the cells
within the brain. Quantification of the signal in the
hippocampus was performed by measuring the average
AD E
B C
Fig. 3 NIS-Hipp-NSCs are viable, proliferate, and express NSC markers. MTS-based analysis of cell viability (a) and proliferation (b) of Hipp-NSCs
transduced with the hNIS (NIS-Hipp-NSCs) compared with naïve Hipp-NSCs. N = 3; P > 0.05 by Student’s t test. c Hipp-NSCs and NIS-Hipp-NSCs
were exposed to 99mTc for 30 min. MTS-based analysis of cell viability was performed 48 h later. N = 3; P > 0.05 by Student’s t test. d Western blot
analysis of total protein extracts from NIS-Hipp-NSCs and naïve Hipp-NSCs grown under proliferating conditions. e Densitometric analysis. The
expression of GAPDH was used to normalize the densitometry value index (DVI). N = 3; P > 0.05 by Student’s t test. GAPDH glyceraldehyde
3-phosphate dehydrogenase, Hipp-NSC hippocampus-derived neural stem cell, hNIS human sodium iodide symporter, MTS 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the
human sodium iodide symporter, NSC neural stem cell, 99mTc technetium-99m
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analysis software (Image J) and correlated to the number
of cells injected (Fig. 6b). Post-imaging analysis of the
rat brains confirmed the presence of the cells by im-
munofluorescence analysis (Fig. 6c).
In a second set of experiments, NIS-Hipp-NSCs were
injected through an intracranial cannula implanted in
the rat brain. For these experiments, NIS-Hipp-NSCs
were resuspended in PBS and injected in the brain (1–
2×105 cells in 5 μl at 0.2 μl/min). At various time pointsafter cell injection (2 and 24 h), 99mTc was delivered to
the brain via the cannula (0.5 mCi in 5 μl at a speed of
0.5 μl/min), and the rats were subjected to SPECT/CT
imaging 4 h later (Fig. 7).
These data demonstrate that Hipp-NSCs expressing
the hNIS can be visualized in vivo in the rat brain. Spe-
cifically, these data show adequate spatial resolution and
signal detection sensitivity of the SPECT imaging system
and the feasibility to repetitively image grafted NSCs in
the rat brain.
AB
Fig. 4 Differentiation potential of NIS-Hipp-NSCs. a Immunofluorescence analysis of Hipp-NSCs transduced with the hNIS (NIS-Hipp-NSCs) and of
naïve Hipp-NSCs cultured in differentiation medium for 7 days. Nuclei are counterstained blue with DAPI. b Western blot analysis of total protein
extracts from differentiated NIS-Hipp-NSCs and naïve Hipp-NSCs. The expression of GAPDH was used to normalize the densitometry value index
(DVI). N = 3; *P < 0.05 by Student’s t test. DAPI 4′,6-diamidino-2-phenylindole, GAPDH glyceraldehyde 3-phosphate dehydrogenase, Hipp-NSC
hippocampus-derived neural stem cell, hNIS human sodium iodide symporter, NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the
human sodium iodide symporter
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transplantation in the rat brain
To determine whether the expression of the hNIS would
alter the ability of Hipp-NSCs to graft and survive after
transplantation in the intact rat brain, Hipp-NSCs ex-
pressing the hNIS were injected in the hippocampus of
adult rats and the animals were euthanized 2 weekslater. Control groups consisted of rats that were injected
with Hipp-NSCs without the hNIS. Grafted cells in the
brain were localized on the basis of the presence of
CMFDA (a cell tracker dye that was loaded in the cells
before transplantation). Both Hipp-NSCs and Hipp-
NSCs expressing the hNIS were found grafted in the
hippocampus 2 weeks after transplantation. Grafted cells
AB
C
Fig. 5 SPECT imaging of NIS-Hipp-NSCs. a SPECT signal from hNIS-Hipp-NSCs and Hipp-NSCs that were incubated with 99mTc for 30 min and
washed in phosphate-buffered saline before imaging. The SPECT signal is shown superimposed on the CT scan image. b SPECT signal recorded
from NIS-Hipp-NSCs that were incubated with 99mTc in vitro before transplantation in the right lateral ventricle. Transverse, coronal, and sagittal
orientations of the brain are shown. c Analysis of the brain shows grafted cells (identified by the expression of GFP) in the ventricle. The expression of
the NIS in the grafted cells was confirmed by immunofluorescence by using an antibody against hNIS (inset). CT computed tomography, GFP green
fluorescent protein, Hipp-NSC hippocampus-derived neural stem cell, hNIS human sodium iodide symporter, NIS sodium iodide symporter,
NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the human sodium iodide symporter, SPECT single-photon emission tomography,
99mTc technetium-99m
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cells were also visible between the CA1 and granular
layer. Phenotypical characterization of the grafted cells
performed by immunofluorescence analysis revealed that
some of the grafted cells had differentiated into mature
neuronal cells expressing NeuN (Fig. 8).Discussion
NIS expression in NSCs
The first objective of this work was to determine the
effect of NIS expression on the biology of NSCs. The
analysis of the effect of the expression of NIS on Hipp-
NSCs was directed to both the basic biological
AB
C
Fig. 6 (See legend on next page.)
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Fig. 6 In vivo SPECT imaging of NIS-Hipp-NSCs injected in the brain hippocampus. a SPECT signal recorded from NIS-Hipp-NSCs that were
incubated with 99mTc in vitro before transplantation in the hippocampus (two sites/hippocampus). Transverse, coronal, and sagittal orientations of
the brain are shown. b Correlation between the number of cells injected in the hippocampus and the signal detected by SPECT imaging. Correlation
coefficient r = 0.9566; two-tailed P value = 0.0108. c Analysis of the brain shows grafted cells (identified by the expression of GFP) in the hippocampus.
The expression of the NIS in the grafted cells was confirmed by immunofluorescence by using an antibody against hNIS (inset). GFP green
fluorescent protein, Hipp-NSC hippocampus-derived neural stem cell, hNIS human sodium iodide symporter, NIS sodium iodide symporter,
NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the human sodium iodide symporter, SPECT single-photon emission tomography,
99mTc technetium-99m
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host brain tissue in vivo. Our data show that the expres-
sion of NIS in Hipp-NSCs does not change their prolif-
eration rate in vitro. The ability to proliferate is a key
functional signature of NSCs and is of particular import-
ance in clinical applications because in vitro NSC expan-
sion is necessary to generate a clinically useful numberA
B
C
Fig. 7 Repetitive in vivo SPECT imaging of NIS-Hipp-NSCs. a CT scan
of the rat head showing the placement of the cannula used to
deliver 99mTc into the brain. b SPECT imaging of the brain of a rat
that had received 99mTc and no cells. c SPECT signal recorded from
the rat brain 2 and 24 h after NIS-Hipp-NSC intracranial injection
following delivering of 99mTc. Transverse and coronal slice orientations
are shown. CT computed tomography, NIS-Hipp-NSC hippocampus-
derived neural stem cell expressing the human sodium iodide
symporter, SPECT single-photon emission tomography,
99mTc technetium-99mof cells for transplantation. Biochemical expression of
proteins that are characteristically found in NSCs (SOX2
and nestin) was also not affected by the NIS. Although
the expression of SOX2 and nestin is commonly used to
identify NSCs, a more complete analysis of their bio-
chemical profile and of their karyotype should be per-
formed in future studies. Nonetheless, the results shown
in this work demonstrate that the exogenous expression
of NIS in Hipp-NSCs does not alter the basic biological
properties of the cells. This is in agreement with other
studies that have characterized the use of the NIS in
other types of stem cells.
Possibly the most important feature of NSCs, and one
that makes these cells so appealing for use in replace-
ment therapy of the nervous system, is their ability to
generate neurons and glia. This important feature is
maintained in Hipp-NSCs that express the NIS, as dem-
onstrated by the expression of proteins that are known
markers of differentiated phenotypes—βIII-tubulin and
NeuN for neurons and glial fibrillary acidic protein
(GFAP) and oligodendrocyte-specific protein for glia—a-
nalyzed by using both immunofluorescence and Western
blot techniques. Additionally, no differences were found
between Hipp-NSCs expressing the NIS and naïve Hipp-
NSCs when comparing the expression of neuronal and
glial markers by Western blot analysis. This is true both
in vitro as well as in vivo in the rat brain, where Hipp-
NSCs expressing the NIS where found grafted in the
hippocampus 2 weeks after transplantation with at least
some cells showing expression of neuronal markers. Al-
though the studies presented in this report are limited to a
2-week follow-up, a large body of literature testifies to the
safety of 99mTc accumulation in cells in vivo [16, 21–23].
Specifically, NIS-based imaging has been validated and
used in humans [24, 25], thus supporting the translational
potential of this reporter system.
Molecular imaging of NSCs using the NIS
The main goal of this work was to develop an imaging
system that will allow tracking NSCs after transplant-
ation in the brain. We have provided several pieces of
evidence, in vitro and in vivo, that the expression of the
reporter gene hNIS allows the visualization of live and
viable Hipp-NSCs by using SPECT imaging. We have
Fig. 8 In vivo SPECT imaging of NIS-Hipp-NSCs injected in the brain hippocampus. Representative cross-sections of rat brain 2 weeks after
transplantation of NIS-Hipp-NSCs or Hipp-NSCs in the hippocampus (CA1 region). Grafted cells are located on the basis of the expression of the
cell tracker dye CMFDA. Mature neurons are identified on the basis of the expression of NeuN. Merged images show that some of the grafted
cells express the neuronal marker NeuN (arrows). Cell nuclei are stained blue with DAPI. Scale bar = 50 μm. DAPI 4′,6-diamidino-2-phenylindole,
Hipp-NSC hippocampus-derived neural stem cell, NIS-Hipp-NSC hippocampus-derived neural stem cell expressing the human sodium iodide
symporter, SPECT single-photon emission tomography
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Hipp-NSCs is functional in that it allows for the select-
ive uptake of 99mTc inside the cells. 99mTc is a gamma-
emitting radioisotope that is taken up by the NIS in
place of iodide (the endogenous, biological ligand of
the NIS). Moreover, 99mTc is widely available and cur-
rently approved by the US Food and Drug Adminis-
tration in combination with SPECT imaging for
diagnostic purposes.
In the in vivo experiments, 99mTc was delivered dir-
ectly in the brain parenchyma where the cells were
grafted. The results demonstrate that the Hipp-NSCs
grafted in the brain are viable, can take up 99mTc via the
NIS, and can be visualized by SPECT imaging.
A successful imaging system needs to have suffi-
cient signal sensitivity to detect grafted cells and suf-
ficient spatial resolution to determine their location
within the tissue/organ. The data presented in this
article demonstrate that NIS combined with SPECT/
CT imaging possesses enough spatial resolution and
sensitivity to detect viable grafted cells in the brain.
Specifically, when Hipp-NSCs were injected at differ-
ent sites within the hippocampus and at different
densities, discrete regions of positive signals were de-
tected and a correlation between the signal intensity
and the number of cells injected could be derived.
Another important result of this work is the demon-
stration that Hipp-NSCs can be visualized repetitively
over time on the same rat. This is a critical aspect of
a reporter gene imaging system because, by allowing
the visualization of grafted cells over time and for as
long as they are viable, it sets this system apart from
other imaging methodologies.Limitations
One limitation of using the hNIS reporter system for im-
aging cells in the brain parenchyma is the relatively low
permeability of 99mTc through the blood–brain barrier
(BBB). In this report, therefore, we opted to use an intra-
cranial cannula to deliver 99mTc directly to the brain in
order to bypass any potential issue with 99mTc penetra-
tion through the BBB. This allowed us to provide proof-
of-principle data demonstrating the feasibility of tracking
grafted NSCs in the brain by using the NIS reporter sys-
tem and SPECT detection. More clinically relevant and
non-invasive delivery routes for 99mTc have been re-
ported, including intravenous injections to image intra-
cranial gliomas in experimental animals [26, 27],
injection into the olfactory route [28, 29], encapsulation
of 99mTc into liposomes, or nanoparticles targeted to the
CNS via specific BBB transporters or receptor systems
[30–32]. In future studies, we will test these routes of
delivery; however, even as it stands, our data show that
delivery of 99mTc via implanted intracranial cannulas is a
valuable method for tracking NSCs in the brain in pre-
clinical animal models of disease that will allow re-
searchers to follow cell grafts over time in the same
animals. This not only will provide valuable information
on the location and viability of the cells and their bio-
logical activity but also will significantly shorten the time
and reduce the number of experimental animals needed
to perform the studies, thus expediting the translation of
stem cell therapy to the clinical setting.
Although here we used NSCs isolated from the hippo-
campus of adult rats (Hipp-NSCs), it has to be noted
that more easily accessible sources of NSCs (i.e., induced
pluripotent stem cells, embryonic stem cell-derived NSCs,
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from bone marrow, fat, or umbilical cord) have been
described and are clinically attractive sources of cells as
they allow autologous transplantation, an appealing ap-
proach that eliminates the need for immunosuppressive
therapies. Because NSCs share common basic biological
properties, the results of this work are significant, as
they lay the groundwork for the use of the NIS to
image NSCs and can very likely be extrapolated to
other sources of NSCs.
Additionally, it is important to notice that in this study
the cells were transplanted in naïve/uninjured rats. The
response of Hipp-NSCs to an injured (i.e., after trau-
matic brain injury) or diseased brain will likely differ.
However, a detailed analysis of grafting and differenti-
ation potentials of Hipp-NSCs in the injured and unin-
jured brain goes beyond the scope of this work and will
be the focus of future studies.
Conclusions
In this report, we have characterized the NIS as a reporter
gene for imaging NSCs in the brain. Developing non-
invasive imaging of grafted cells has emerged as a funda-
mental tool to advance the field of stem cell therapy. The
ability to track cells in vivo after transplantation on the
same animal over time will allow a reduction in the num-
ber of experimental animals needed to determine the opti-
mal source of cells as well as the best route and site of
delivery that will produce a functional recovery in animal
models of disease. This will significantly shorten the time
between experimental animal work and translation to the
clinical setting.
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